Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium

Recruiting N/A Interventional Study
Endometrial Cancer Atypical Hyperplasia Bariatric Surgery Candidate
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 41
Sex
Female
Study type
Interventional
Purpose
Treatment
Participants needed
36 (estimated)
Sponsor
University Health Network, Toronto · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
A growing population of young women with obesity are developing atypical hyperplasia (pre-cancer) and endometrial cancer. Progestin is the standard treatment for women who wish to preserve fertility, but this approach does not address the underlying cause of endometrial cancer/atypical hyperplasia (obesity); thus response rates are low and recurrence rates are high. Significant weight loss by bari…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * BMI ≥ 35 * Diagnosis of grade 1 endometrioid endometrial cancer or complex atypical hyperplasia * Clinical stage 1 disease - no evidence of metastatic disease beyond the uterus by imaging performed (MRI, CT) * ECOG status \<2 * Desire for fertility preservation * No contraindi…
Contacts

Tara Zad

416-946-4501

Tara.Zad@uhn.ca

CONTACT